Published in Hepatitis Weekly, April 17th, 2006
P. Braitstein and colleagues, University of Bern, wrote that the study was done "to characterize the impact of HCV serostatus on adherence to antiretroviral treatment (ART) among HIV-infected adults initiating ART."
They continued, "The British Columbia HIV/AIDS Drug Treatment Program distributes, at no cost, all ART in this Canadian province. Eligible individuals used triple combination ART as their first HIV therapy and had...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly